Health Catalyst, Inc. (NASDAQ:HCAT) Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. increased its stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 6.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 29,469 shares of the company’s stock after purchasing an additional 1,907 shares during the quarter. Principal Financial Group Inc.’s holdings in Health Catalyst were worth $188,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Primecap Management Co. CA lifted its holdings in shares of Health Catalyst by 26.7% during the fourth quarter. Primecap Management Co. CA now owns 1,419,577 shares of the company’s stock worth $13,145,000 after purchasing an additional 299,139 shares during the period. Nepsis Inc. lifted its holdings in shares of Health Catalyst by 8.3% during the second quarter. Nepsis Inc. now owns 1,253,080 shares of the company’s stock worth $8,007,000 after purchasing an additional 95,686 shares during the period. Kennedy Capital Management LLC acquired a new stake in shares of Health Catalyst during the first quarter worth $8,780,000. Acadian Asset Management LLC lifted its holdings in shares of Health Catalyst by 38.3% during the first quarter. Acadian Asset Management LLC now owns 724,560 shares of the company’s stock worth $5,453,000 after purchasing an additional 200,494 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Health Catalyst by 19.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 521,362 shares of the company’s stock worth $4,828,000 after purchasing an additional 85,777 shares during the period. 85.00% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on HCAT shares. Piper Sandler cut their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 26th. Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 price objective on shares of Health Catalyst in a research report on Tuesday, May 21st. JPMorgan Chase & Co. increased their price objective on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Evercore ISI cut their price objective on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a research report on Tuesday, July 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research report on Tuesday, August 20th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.42.

Insider Buying and Selling

In related news, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the sale, the chief operating officer now owns 140,108 shares in the company, valued at approximately $1,062,018.64. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares in the company, valued at approximately $1,847,460.82. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now owns 140,108 shares of the company’s stock, valued at approximately $1,062,018.64. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,037 shares of company stock worth $236,872. 2.70% of the stock is owned by corporate insiders.

Health Catalyst Stock Up 5.2 %

Shares of HCAT stock opened at $8.44 on Monday. Health Catalyst, Inc. has a fifty-two week low of $5.42 and a fifty-two week high of $11.41. The stock has a market cap of $498.26 million, a P/E ratio of -4.56 and a beta of 1.31. The business has a fifty day simple moving average of $7.05 and a 200-day simple moving average of $6.89.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The business had revenue of $75.90 million during the quarter, compared to analysts’ expectations of $74.96 million. During the same quarter last year, the business posted ($0.21) earnings per share. The business’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, sell-side analysts anticipate that Health Catalyst, Inc. will post -0.35 earnings per share for the current year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.